BioCentury
ARTICLE | Company News

EUSA acquires global rights to J&J's Sylvant

July 20, 2018 4:04 PM UTC

Johnson & Johnson (NYSE:JNJ) granted EUSA Pharma Ltd. (Hemel Hempstead, U.K.) worldwide rights to Sylvant siltuximab for $115 million in cash...

BCIQ Target Profiles

Interleukin-6 (IL-6)